Commit b8f3fd4d authored by Mathieu Giraud's avatar Mathieu Giraud
Browse files

doc/ new papers

parent daf7b0e5
Pipeline #264828 passed with stages
in 5 minutes and 42 seconds
......@@ -178,6 +178,11 @@ Michaela Kotrova et al.,
Cytometry Part A, 93(11):1118-1124, 2018
Anton W. Langerak,
*High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges*,
Journal of Immunology, 2017, 198(10):3765-3774,
Zhenhua Li et al.,
*Identifying IGH disease clones for MRD monitoring in childhood B-cell acute lymphoblastic leukemia using RNA-Seq*,
Leukemia, 2020, 34:2418-2429,
......@@ -208,6 +213,11 @@ Edit Porpaczy et al.,
Blood, 2018,
Rathana Kim et al.,
*Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation*,
Leukemia, 2020, 34, 1730-1740,
Mikaël Salson et al.,
*High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones*,
Leukemia Research, 2017, 53, 1–7,
......@@ -248,6 +258,10 @@ Amelie Trinquand et al.,
medRxiv 2020.09.08.20189829,
Patrik Villarèse et al.,
*One step next generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukemia*,
ed. Anton W. Langerak, Methods in Molecular Biology, forthcoming
Gary Wright et al.,
*Clinical benefit of a high‐throughput sequencing approach for minimal residual disease in acute lymphoblastic leukemia*,
Pediatric Blood & Cancer, 2019,
Markdown is supported
0% or .
You are about to add 0 people to the discussion. Proceed with caution.
Finish editing this message first!
Please register or to comment